Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)
NCT06034886 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-01-09
Summary
The purpose of this expanded access protocol is to provide access to the investigational drug troriluzole in patients with spinocerebellar ataxia (SCA).
Conditions
- SCA
- Spinocerebellar Ataxias
Interventions
- DRUG
-
Troriluzole
BHV-4157 140mg, 200mg or 280mg once daily by mouth.
Sponsors & Collaborators
-
Biohaven Pharmaceuticals, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
NCT05490563 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Riluzole in Patients With Spinocerebellar Ataxia Type 7
NCT03660917 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3
NCT05160558 ·Status: TERMINATED ·Phase: PHASE1
-
Open Pilot Trial of BHV-4157
NCT03408080 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of CAD-1883 for Spinocerebellar Ataxia
NCT04301284 ·Status: WITHDRAWN ·Phase: PHASE2
-
Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3
NCT01096095 ·Status: WITHDRAWN ·Phase: PHASE2
-
Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3
NCT01096082 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis
NCT07093268 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Clinical Trial Readiness for SCA1 and SCA3
NCT03487367 ·Status: UNKNOWN
-
Efficacy of Riluzole in Hereditary Cerebellar Ataxia
NCT01104649 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study of Resveratrol as Treatment for Friedreich Ataxia
NCT01339884 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury
NCT01484184 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)
NCT06069934 ·Status: NO_LONGER_AVAILABLE
-
Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia
NCT01016366 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Nilotinib in Cerebellar Ataxia Patients
NCT03932669 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Effects of Oral Trehalose In Patients With Spinocerebellar Ataxia 3
NCT04426149 ·Status: COMPLETED ·Phase: NA
-
Safety and Tolerability of Lithium in Spinocerebellar Ataxia 2 (SCA2)
NCT00998634 ·Status: COMPLETED ·Phase: PHASE2
-
A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
NCT06673056 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside
NCT06324877 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia
NCT00202397 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia
NCT03214588 ·Status: COMPLETED ·Phase: PHASE2
-
Stemchymal® for Polyglutamine Spinocerebellar Ataxia
NCT06397274 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis (STEMALS)
NCT06344260 ·Status: RECRUITING ·Phase: PHASE2
-
Pivotal Study of N-acetyl-L-leucine for CACNA1A
NCT07221292 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL)
NCT03347344 ·Status: COMPLETED ·Phase: PHASE3